BDX Becton Dickinson and Company

New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma

FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, enabling more researchers across a wider range of applications to uncover deeper insights and dynamics from cells once invisible in flow cytometry experiments – with increased ease and throughput.

BD SpectralFX™ Technology maximizes the number of colors that can be used in flow cytometry, allowing scientists to analyze up to 50 or more characteristics of a single cell at one time, with optimal resolution and sensitivity, which is ideal for scientists pursuing novel biomarker discovery. BD CellView™ Image Technology enables high-speed fluorescent and label-free imaging of single cells, revealing precise spatial and morphological insights – like the location of a virus or protein within a single cell, or the microscopic interaction between two cells – that can be visually confirmed and analyzed in real time. Combining these technologies, which were first introduced in the BD FACSDiscover™ S8 Cell Sorter and profiled on the cover of the journal Science, the BD FACSDiscover™ A8 Cell Analyzer enables scientists to capture more insights per experiment than ever, with exceptional depth, speed and sensitivity.

Additional advancements on the BD FACSDiscover™ A8 Cell Analyzer are specifically designed to power translational research. Highlights include:

• High-throughput, walkaway automation that enables best-in-class cost-per-insight economics
• New intuitive software workflows that allow for effective management of large datasets, for improved system usability
• Seamless pairing with the industry-leading ecosystem of BD FACSDiscover™ Cell Sorters and BD Reagents

"The BD FACSDiscover™ A8 Cell Analyzer signals an exciting step forward for researchers in areas like immuno-oncology that require tools delivering excellent reproducibility and performance, while managing budget constraints," said Rui Gardner, head of Flow Cytometry Core Facility at Memorial Sloan Kettering Cancer Center, an early access collaboration site. "Our investigators have already learned so much using this new technology, and we look forward to performing deep immunophenotyping for high-fidelity biomarker discovery to elucidate insights that can advance research and improve human health."

Steve Conly, worldwide president of BD Biosciences, added, "Translational research, in particular, is growing at a rapid pace and the BD FACSDiscover™ A8 Cell Analyzer combines advanced science with ease of use to empower, like never before, scientists developing the next generation of potentially life-changing therapies. Paired with the BD FACSDiscover™ S8 Cell Sorter, and alongside our advancements in software, informatics, and reagents, this landmark cell analyzer will enable new dimensions of possibilities in one state-of-the-art ecosystem."

New software innovations launching alongside the instrument include the latest version of BD FACSChorus™ Software, which simplifies workflows on both the BD FACSDiscover™ A8 Cell Analyzer as well as FACSDiscover™ S8 Cell Sorter, and the faster, easier-to-use analysis software FlowJo™ v11. All three products will be featured at the International Society for Advancement of Cytometry CYTO 2025 event at booth 615 from May 31 to June 4 in Denver. The BD FACSDiscover™ A8 Cell Analyzer is now available to order through local sales representatives, and through a forthcoming FACSDiscover™ Partner Program initially in select regions that gives customers added flexibility and support. More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

SOURCE BD (Becton, Dickinson and Company)